Vanguard Asset Management
NTLA icon

Vanguard Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Vanguard Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
87,849
+6,971
+9% +$97.6K ﹤0.01% 1694
2026
Q1 		$1.04M Buy
+80,878
New +$1.03M ﹤0.01% 1772

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Vanguard Asset Management's NTLA Position: Q2 2026 in Review

Vanguard Asset Management increased its Intellia Therapeutics (NTLA) stake by 8.6% in Q2 2026, buying an estimated $97.6K and bringing the position to 87,849 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

Vanguard Asset Management first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 322 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Vanguard Asset Management held 87,849 shares of Intellia Therapeutics worth $1.49M as of Q2 2026.
  • Vanguard Asset Management bought 6,971 Intellia Therapeutics shares in Q2 2026, an estimated $97.6K.
  • Intellia Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1694 holding.
  • Vanguard Asset Management first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 322 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.